May 7 |
Theriva Biologics GAAP EPS of -$0.30
|
May 7 |
Theriva™ Biologics Reports First Quarter 2024 Operational Highlights and Financial Results
|
Apr 25 |
Theriva™ Biologics to Discuss the Trial Design for VIRAGE - a Phase 2b Clinical Study of Systemically Administered VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma - at the 2024 American Society of Clinical Oncology (ASCO) An...
|
Apr 23 |
Theriva™ Biologics Announces Positive Topline Data from Investigator Sponsored Phase 1 Trial of Intravitreal VCN-01 in Pediatric Patients with Refractory Retinoblastoma
|
Apr 22 |
Theriva™ Biologics to Present Preclinical Data Supporting the Potential Synergy of VCN-01 and First-Line Pancreatic Cancer Chemotherapy Regimens at the American Society for Cell and Gene Therapy 27th Annual Meeting
|
Apr 8 |
Theriva™ Biologics Announces Presentation at the American Society for Cell and Gene Therapy 27th Annual Meeting
|
Mar 25 |
Earnings Scheduled For March 25, 2024
|
Mar 22 |
Preview: Theriva Biologics's Earnings
|
Mar 22 |
Theriva Biologics FY 2023 Earnings Preview
|
Mar 19 |
Theriva™ Biologics to Host Conference Call and Webcast to Discuss Full Year 2023 Operational Highlights and Financial Results
|